Arvinas Inc.
5 Science Park
395 Winchester Ave
New Haven
Connecticut
06511
United States
Website: https://www.arvinas.com/
About Arvinas Inc.
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.
QUALITY BENEFITS
Designed with health and wellness in mind, employees and their families are eligible for:
- Medical, dental, and vision options, including a generous company contribution into an HSA
- Paid maternity and paternity leave
- FSA, HSA, Healthcare, and Dependent Care accounts
- Company provided life insurance and short/long-term disability coverage
- Additional voluntary benefits including critical illness, hospital care and more
COMPENSATION & EQUITY
Central to our organization is attracting, retaining and engaging the best and brightest by sharing in the success of our organization:
- Competitive salaries and an annual incentive program
- 401K matching program with immediate vesting
- Eligibility for long-term equity incentives upon hire and annually
TIME OFF
We believe it’s important to relax, unwind and enjoy life’s moments:
- Paid vacation
- A year-end office closure
- Observed company holidays
- Paid sabbatical upon 5 years’ tenure
We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. We take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.
Working at Arvinas
116 articles about Arvinas Inc.
-
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
10/27/2022
Arvinas, Inc. announced Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute/Harvard Medical School as the winner of the 2022 Arvinas Early Career Research Award last night at the 5th Annual Targeted Protein Degradation Summit in Boston.
-
Arvinas Gives Back to Local Greater New Haven Community
9/30/2022
Arvinas, Inc. announced that nearly 200 employees participated in the Company’s inaugural “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area.
-
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
-
Arvinas Announces Changes to its Board of Directors
8/18/2022
Arvinas, Inc. announced that Liam Ratcliffe, M.D., Ph.D. has stepped down from the company’s Board and John Young has been appointed to join.
-
Arvinas Appoints John Northcott as Chief Commercial Officer
8/1/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO).
-
Foundation Medicine Announces Strategic Collaboration with Arvinas
6/5/2022
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne®Liquid CDx as a companion diagnostic for use with Arvinas’ bavdegalutamide, an investigational novel PROTAC® protein degrader targeting the androgen receptor.
-
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
6/2/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif.
-
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
6/1/2022
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced a global call for entries for their inaugural Early Career Research Award.
-
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/5/2022
Arvinas, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
5/3/2022
Arvinas, Inc. announced that management will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10 at 7:00 p.m. ET /4:00 p.m. PT in Las Vegas.
-
Arvinas to Present at Upcoming Investor Conferences
3/4/2022
Arvinas, Inc. today announced that it will participate in two upcoming virtual investor conferences: Cowen & Co. 42nd Annual Health Care Conference on Monday, March 7.
-
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2/28/2022
Arvinas, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
2/17/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced completed Phase 1 and interim Phase 2 ARDENT data for bavdegalutamide (ARV-110), a novel PROTAC® degrader targeting the androgen receptor (AR).
-
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
2/14/2022
Arvinas, Inc. (Nasdaq: ARVN), today announced the presentation of new data showing that bavdegalutamide (also known as ARV-110), a novel PROTAC® protein degrader targeting the androgen receptor (AR), continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC).
-
Arvinas to Present at Upcoming Investor Conferences - Feb 03, 2022
2/3/2022
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it will participate in two upcoming virtual investor conferences.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
-
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
12/10/2021
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced an update on Phase 1 dose escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).
-
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
11/19/2021
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471 will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021.